NKTX
Price:
$2.13
Market Cap:
$152.39M
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, Ca...[Read more]
Industry
Biotechnology
IPO Date
2020-07-10
Stock Exchange
NASDAQ
Ticker
NKTX
According to Nkarta, Inc.’s latest financial reports and current stock price. The company's current ROE is -30.90%. This represents a change of 294.06% compared to the average of -7.84% of the last 4 quarters.
The mean historical ROE of Nkarta, Inc. over the last ten years is -13.56%. The current -30.90% ROE has changed 127.78% with respect to the historical average. Over the past ten years (40 quarters), NKTX's ROE was at its highest in in the June 2020 quarter at 212.12%. The ROE was at its lowest in in the March 2019 quarter at -42.16%.
Average
-13.56%
Median
-29.51%
Minimum
-43.00%
Maximum
82.71%
Discovering the peaks and valleys of Nkarta, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.53%
Maximum Annual ROE = 82.71%
Minimum Annual Increase = -134.39%
Minimum Annual ROE = -43.00%
| Year | ROE | Change |
|---|---|---|
| 2025 | -33.33% | 24.97% |
| 2024 | -26.67% | -37.98% |
| 2023 | -43.00% | 40.58% |
| 2022 | -30.58% | -10.83% |
| 2021 | -34.30% | 20.59% |
| 2020 | -28.44% | -134.39% |
| 2019 | 82.71% | 1.53% |
The current ROE of Nkarta, Inc. (NKTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-34.33%
5-year avg
-33.57%
10-year avg
-13.56%
Nkarta, Inc.’s ROE is greater than Alector, Inc. (-295.17%), greater than PepGen Inc. (-59.89%), greater than Fate Therapeutics, Inc. (-58.89%), greater than Molecular Partners AG (-66.19%), greater than Cassava Sciences, Inc. (-99.85%), greater than Applied Therapeutics, Inc. (-348.18%), greater than Cybin Inc. (-72.37%), greater than Elicio Therapeutics, Inc. (-2748.16%), less than Vor Biopharma Inc. (87.31%), greater than Forte Biosciences, Inc. (-106.16%),
| Company | ROE | Market cap |
|---|---|---|
| -295.17% | $168.76M | |
| -59.89% | $118.28M | |
| -58.89% | $275.08M | |
| -66.19% | $147.42M | |
| -99.85% | $63.77M | |
| -348.18% | $14.86M | |
| -72.37% | $413.02M | |
| -2748.16% | $55.10M | |
| 87.31% | $133.99M | |
| -106.16% | $1.57B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nkarta, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Nkarta, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Nkarta, Inc.'s ROE?
How is the ROE calculated for Nkarta, Inc. (NKTX)?
What is the highest ROE for Nkarta, Inc. (NKTX)?
What is the 3-year average ROE for Nkarta, Inc. (NKTX)?
What is the 5-year average ROE for Nkarta, Inc. (NKTX)?
How does the current ROE for Nkarta, Inc. (NKTX) compare to its historical average?